Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)

NCT03961815 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03961815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03961815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
January 6, 2020
Completion date
September 19, 2023
Enrollment
18 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ibd